Lincoln Capital LLC increased its position in Pfizer Inc. (NYSE:PFE) by 1.1% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 8,443 shares of the biopharmaceutical company’s stock after buying an additional 94 shares during the period. Lincoln Capital LLC’s holdings in Pfizer were worth $297,000 at the end of the most recent reporting period.
Several other institutional investors also recently bought and sold shares of PFE. Stelac Advisory Services LLC bought a new position in Pfizer during the second quarter worth approximately $110,000. Catamount Wealth Management raised its stake in Pfizer by 14.2% in the first quarter. Catamount Wealth Management now owns 4,395 shares of the biopharmaceutical company’s stock valued at $130,000 after buying an additional 545 shares in the last quarter. Commonwealth Financial Services LLC raised its stake in Pfizer by 5.5% in the second quarter. Commonwealth Financial Services LLC now owns 4,023 shares of the biopharmaceutical company’s stock valued at $142,000 after buying an additional 210 shares in the last quarter. Stuart Chaussee & Associates Inc. raised its stake in Pfizer by 64.3% in the second quarter. Stuart Chaussee & Associates Inc. now owns 5,430 shares of the biopharmaceutical company’s stock valued at $193,000 after buying an additional 2,125 shares in the last quarter. Finally, Jag Capital Management LLC acquired a new stake in Pfizer during the second quarter valued at about $202,000. 69.65% of the stock is owned by hedge funds and other institutional investors.
Shares of Pfizer Inc. (NYSE:PFE) traded down 1.81% during mid-day trading on Monday, hitting $33.64. The stock had a trading volume of 29,509,548 shares. The stock has a market cap of $204.05 billion, a P/E ratio of 29.82 and a beta of 0.87. Pfizer Inc. has a 52-week low of $28.25 and a 52-week high of $37.39. The company’s 50 day moving average is $34.68 and its 200-day moving average is $33.90.
Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, August 2nd. The biopharmaceutical company reported $0.64 EPS for the quarter, beating the Zacks’ consensus estimate of $0.62 by $0.02. Pfizer had a net margin of 14.88% and a return on equity of 23.37%. The firm earned $13.10 billion during the quarter, compared to the consensus estimate of $13.01 billion. During the same quarter last year, the firm earned $0.56 EPS. The firm’s revenue for the quarter was up 10.9% compared to the same quarter last year. On average, equities research analysts anticipate that Pfizer Inc. will post $2.46 earnings per share for the current fiscal year.
The firm also recently declared a quarterly dividend, which will be paid on Thursday, December 1st. Investors of record on Friday, November 11th will be issued a $0.30 dividend. This represents a $1.20 dividend on an annualized basis and a dividend yield of 3.57%. The ex-dividend date is Tuesday, November 8th. Pfizer’s payout ratio is 95.24%.
PFE has been the subject of several research analyst reports. Vetr raised Pfizer from a “buy” rating to a “strong-buy” rating and set a $37.94 price objective for the company in a research note on Monday, June 27th. Deutsche Bank AG reissued a “buy” rating and set a $44.00 price objective on shares of Pfizer in a research note on Thursday, August 18th. Credit Suisse Group AG reissued an “outperform” rating and set a $40.00 price objective on shares of Pfizer in a research note on Monday, August 22nd. Piper Jaffray Cos. set a $54.00 price objective on Pfizer and gave the company a “buy” rating in a research note on Tuesday, August 23rd. Finally, Jefferies Group set a $41.50 price objective on Pfizer and gave the company a “buy” rating in a research note on Thursday, July 14th. Ten analysts have rated the stock with a hold rating, fifteen have given a buy rating and one has issued a strong buy rating to the company. The stock currently has an average rating of “Buy” and a consensus target price of $38.78.
Pfizer Inc is a research-based global biopharmaceutical company. The Company is engaged in discovering, developing and manufacturing of healthcare products. Its portfolio includes medicines, vaccines and medical devices, as well as consumer healthcare products. Its products include Prevnar/Prevenar 13, Lyrica, Enbrel, Lipitor, Viagra, Sutent, BeneFIX, Genotropin, ReFacto, Xyntha and Enbrel.
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).
Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.